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Emerging evidence suggests that a simple cross-linking reaction through ionic interaction may be the 
primary cause of the heparin-accelerated antithrombin inhibition of cu-thrombin. 
Heparin Antithrombin Thrombin 
1. INTRODUCTION 
The molecular mecha~sm of heparin-enh~ced 
antithrombin-thrombin reaction [l-4] is a 
debated subject. Three models are currently 
available to account for the action of heparin. (i) 
The heparin-antithrombin model [5-71 postulates 
that heparin binds to antithrombin and transforms 
antithrombin into a more effective inhibitor. (ii) 
The heparin-thrombin model [8-l I] postulates 
that heparin binds to thrombin and makes throm- 
bin more susceptible to antithrombin inhibition. 
(iii) The ternary (template) model [12-171 
postulates that heparin must interact with both an- 
tithrombin and thrombin to enhance the inhibi- 
tion. The fact that all 3 models are well sustained 
by experimental evidence suggests that a com- 
promised working model must accommodate all 
experimental results supporting each of those 
models. 
the ternary model 1121 may represent the com- 
promise between the heparin-thrombin and 
heparin-antithrombin models as the practical 
working model. This evidence further implies that 
heparin accelerates the formation of the 
antithrombin-thrombin complex by acting 
primarily as a noncovalent cross-linking reagent, 
and that the acidic sulfate groups of heparin cross- 
link antithrombin and thrombin by interacting 
with the basic cross-linking sites of antithrombin 
and thrombin independently. 
This evidence, derived from both chemical and 
kinetic studies, may be summarized as follows: 
There is now growing evidence to indicate that 
* Correspondence and permanent address: R-1056,309 
Ciba-Geigy Ltd., Base1 CH-4002, Switzerland 
Thrombin refers to ~-thrombin unless otherwise 
indicated 
(i) It is now well demonstrated that heparin reacts 
with antithrombin [3,18,19] and thrombin 
[9,11,20-231 independently. The reactions require 
the acidic sulfate groups of heparin [l&24-26] and 
the basic amino acids (Lys and Arg) of both 
antithrombin [3,12,27,30] and thrombin 
[8,10,12,28], In addition to heparin, sulfate 
polymers such as poly~etholesulfonate 127,291, 
dermatan sulfate 131,321, heparan sulfate [32] and 
pentosane polysulfate [33,34] also display heparin- 
like activity in enhancing antithrombin-thrombin 
reaction. 
(ii) Chemical studies [8,10,12] have shown that the 
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heparin binding sites of antithrombin and throm- 
bin are independent of their reactive site and active 
site, respectively. The sensitivity of heparin- 
enhanced antithrombin-thrombin reaction can be 
diminished or abolished by masking the heparin- 
binding site (through chemical modification of Lys 
and Arg) of antithrombin [3,12] and/or thrombin 
[8,10,12,28]. On the other hand, blocking of the 
active site of thrombin does not prevent heparin- 
mediated cross-linking of antithrombin and 
thrombin [ 121. 
(iii) The most convincing evidence for the cross- 
linking mechanism comes from kinetic studies 
which have shown that interactions of both an- 
tithrombin and thrombin with heparin are in- 
volved in the expression of activity [14,17]. At 
fixed concentrations of antithrombin and throm- 
bin, the reaction rates of antithrombin and throm- 
bin always display a bell-shaped curve against the 
increase of heparin concentration [6,14,17,35-371; 
i.e., there is an optimal heparin concentration for 
each reaction mixture with fixed concentrations of 
antithrombin and thrombin. The molar ratios of 
antithrombin/heparin/thrombin observed under 
those optimal conditions are strikingly close to 
1: 1: 1 [14]. These results are characteristic of pro- 
tein cross-linking phenomena: at low concentra- 
tions of heparin, both antithrombin and thrombin 
will compete for binding to heparin; at excess con- 
centrations of heparin, both antithrombin and 
thrombin will be saturated with heparin; and the 
optimal cross-linking reaction occurs when the 
cross-linking reagent and proteins have approx- 
imately equal concentrations. 
Finally, the binding mechanism of this proposed 
cross-linking model bears an interesting 
resemblance to the binding mechanism of the 
hirudin-thrombin complex [38]. Efficient inhibi- 
tion of both hirudin and antithrombin requires in- 
teraction with cu-thrombin through the active site 
as well as an independent basic site [39,40]. This 
resemblance, together with the intriguing sequence 
homology of hirudin and fibrinopeptides [38], sug- 
gets that a common mechanism may account for 
the unique enzymatic specificity of cY-thrombin 
toward both protein inhibitors and protein 
substrates. 
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